News >

Expert Highlights Immunotherapy Use in Stage III NSCLC

Caroline Seymour
Published: Tuesday, Feb 27, 2018

Gary Schwartz, MD

Gary Schwartz, MD
The recent FDA approval of durvalumab (Imfinzi) in locally advanced unresectable stage III non–small cell lung cancer (NSCLC) marks a new era in the landscape, as the agent showed a significant improvement in progression-free survival (PFS) in a phase III trial.

The approval was based on the results of the PACIFIC trial that examined the PD-L1 inhibitor versus placebo. Results showed an improved median PFS of 11.2 months compared with placebo (16.8 vs 5.6 months; HR, 0.52; 95% CI, 0.42-0.65; P <.0001). The 12-month PFS rates were 55.9% versus 35.3%, and the 18-month PFS rate was 44.2% versus 27.0% for durvalumab and placebo, respectively.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication